The Canadian Prevention of Renal and Cardiovascular Endpoints Trial

Summary

Advanced kidney disease with it's associated heart and blood vessel problems are becoming more frequent. These problems markedly affect length and quality of life and cost a lot to treat. Treatments are known that can prevent development of advanced kidney and heart disease. These treatments are not being optimally applied in the current health system. This study aims to identify people with relatively early stage chronic kidney disease. With the participation of these people, the study will test whether a nurse coordinated clinic involving a medical kidney specialist, applying the known treatments, can reduce or delay the onset of advanced kidney disease and heart and blood vessel problems such as heart attack, stroke and death, to a greater extent than usual care. The study will also address issues of costs associated with care and illness. The nature of the care provided by the health care professionals will be studied to see how best to achieve good health outcomes.

Conditions

• Chronic Kidney Disease

Interventions

OTHER

Combined CKD and CVD Prevention

Perindopril, Lisinopril, Captopril, Candesartan, Losartan, Amlodipine, Verapamil, Chlorthalidone

OTHER

Cardiovascular Disease prevention

Atorvastatin, Rosuvastatin, Simvastatin, Aspirin, Clopidogrel

OTHER

Treatment of Chronic Kidney Disease complications

Calcitriol, Calcium carbonate, Erythropoietin, Sodium bicarbonate

OTHER

Usual care

No prescribed intervention, just those that the patient's own family physician thought indicated

Sponsors & Collaborators

• Nova Scotia Health Authority

  collaborator OTHER

• Hopital Charles Lemoyne

  collaborator OTHER

• London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

  collaborator OTHER

• University of British Columbia

  collaborator OTHER

• Brendan Barrett

  lead OTHER

Principal Investigators

• Patrick S Parfrey, MD · Memorial University of Newfoundland

• Brendan J Barrett, MD · Memorial University of Newfoundland

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

40 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-04-30

Primary Completion

2008-05-31

Completion

2008-06-30

Countries

• Canada

Study Locations